Cargando…
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
While most patients with chronic myeloid leukemia (CML) express either e13a2 or e14a2 BCR-ABL1 transcripts, a significant minority expresses variant transcripts, of which e19a2 is the most common. Although considered to have a relatively favourable outcome, reported responses to tyrosine kinase inhi...
Autores principales: | Langabeer, Stephen E., McCarron, Sarah L., Kelly, Johanna, Krawczyk, Janusz, McPherson, Suzanne, Perera, Kanthi, Murphy, Philip T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420773/ https://www.ncbi.nlm.nih.gov/pubmed/22937329 http://dx.doi.org/10.1155/2012/458716 |
Ejemplares similares
-
Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia
por: Kearney, Laura, et al.
Publicado: (2020) -
Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia
por: McCarron, Sarah L., et al.
Publicado: (2013) -
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015) -
Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020) -
Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2023)